Close

CD7

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Product List Background Anti-CD7 CAR-T Services Anti-CD7 CAR-T In Vitro Assay ServicesAnti-CD7 CAR-T In Vivo Assay Services

Product List

For all your needs in CD7 CAR-T cell development, Creative Biolabs is the ultimate answer. Our comprehensive range of products and services ensures a complete solution for our clients. With our team of skilled professionals, we provide assistance with CAR design and construction as well as T cell engineering, ensuring that we fulfill your requirements successfully.

Background

CD7, a cell membrane glycoprotein weighing 40 kDa, serves as a surface receptor. CD7, which is a member of the immunoglobulin supergene family, has the potential to be an effective target for CART. This is primarily due to its extensive expression in nearly all T-cell malignancies.

Associated Diseases

Timeline of CD7 target research. Fig.1 Timeline of CD7 target research.1

Anti-CD7 CAR-T Services

Anti-CD7 CAR-T In Vitro Assay Services

CD7 CAR-T Expression Test

The CAR expression test involves a series of procedures that assess the presence and quantity of chimeric antigen receptors on immune cells. At Creative Biolabs, our unconjugated CD7, biotinylated CD7, fluorescent-labeled CD7, and custom cells with CD7 overexpression bind specifically to the scFv region of the CAR molecule, allowing for sensitive and accurate detection of anti-CD7 CAR expression. The results of the CAR expression test provide valuable information on the success of the genetic modification process and the efficiency of chimeric antigen receptor expression on the immune cells.

Surface expression of CD7 CAR in lentivirus-transduced T cells. Fig.2 Surface expression of CD7 CAR in lentivirus-transduced T cells.2

CD7 CAR-T Cytokine Release Test

We provide CD7 CAR-T cytokine release test, aimed at assessing the cytokine release associated with CD7 CAR-T therapy. Our cytokine release test services employ advanced techniques, such as bead-based multiplex assays and flow cytometry, for the measurement of important cytokines, including IL-6, IL-8, IL-10, and IFNγ. Through precise cytokine measurement, we can evaluate the effectiveness of CAR-T treatment in targeting specific cancers and its overall impact on the immune system.

Changes in cytokines and temperature within the first month after infusion of CD7 CAR T-cells. Fig.3 Changes in cytokines and temperature within the first month after infusion of CD7 CAR T-cells.3

CD7 CAR-T In Vitro Cytotoxicity Assay

Studies have demonstrated that the presence of CD7+ AML blasts can be significantly reduced in the CD7 CAR-T group. Creative Biolabs is pleased to access the cytotoxic activity of anti-CD7 CAR-T cells, facilitating our clients' research.

The primary CD7+ R/R-AML blasts exhibit cytotoxicity due to the presence of CD7 CAR. Fig.4 The primary CD7+ R/R-AML blasts exhibit cytotoxicity due to the presence of CD7 CAR.2

Anti-CD7 CAR-T In Vivo Assay Services

CD7 CAR-T Cell Therapy Animal Models

We will develop a suitable xenograft model to examine the effects of CD7 CAR-T cells in vivo.

mouse model construction and CAR-T-cell. Fig.5 mouse model construction and CAR-T-cell.2

Efficacy Test of CD7 CAR-T

We provide various in vivo assays to evaluate the killing capability and proliferation potential of the CD7 CAR-T cells.

The CD7 CAR-T cells show incredible efficacy against leukemia in a mouse model. Fig.6 The CD7 CAR-T cells show incredible efficacy against leukemia in a mouse model.2

Toxicity Evaluation of CD7 CAR-T

We provide tumor lysis analysis, on-target/off-tumor toxicologic effect analysis, tumorigenicity study, and other custom analysis for toxicity evaluation, monitoring for any signs of toxicity or adverse reactions.

References

  1. Liu, Jile.; et al. "Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances." Frontiers in Immunology 14 (2023): 1170968.
  2. Lu, Yu.; et al. "Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML)." Journal of Translational Medicine 20.1 (2022): 1-13.
  3. Dai, Hai-ping.; et al. "Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma." Biomarker Research 10.1 (2022): 1-5.
  • CAR Vector Products

  • AbTCR Vector Products

  • CAR Cell Products

  • CAR Viral Particles

  • Protein

  • CAR Animal Cells

  • CAR mRNA

Loading...
  • Target Species:
  • Antibody Clone:
  • Antibody Host:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
  • CAR Vector Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
CAR-YF042 Anti-CD7 (CBL-YF009) h(4-1BB-CD3ζ) CAR, pCDCAR1 Human CBL-YF009 Human scFv-4-1BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-YF043 Anti-CD7 (CBL-YF009) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBL-YF009 Human scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP059 Anti-CD7 h(CD28-CD3ζ) CAR, pCDCAR1 Human Humanized scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP3207 Anti-CD7 (TH69) h(CD28-CD3ζ) CAR, pCDCAR1 Human TH69 Humanized scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP3222 Anti-CD7 (8H8.1) h(41BB-CD3ζ) CAR, pCDCAR1 Human 8H8.1 Human scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP3223 Anti-CD7 (124-1D1) h(CD28-CD3ζ) CAR, pCDCAR1 Human 124-1D1 Human scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP3224 Anti-CD7 (124-1D1) h(41BB-CD3ζ) CAR, pCDCAR1 Human 124-1D1 Human scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP3225 Anti-CD7 (MHH-183-S(P)) h(CD28-CD3ζ) CAR, pCDCAR1 Human MHH-183-S(P) Human scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP3226 Anti-CD7 (MHH-183-S(P)) h(41BB-CD3ζ) CAR, pCDCAR1 Human MHH-183-S(P) Human scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP3301 Anti-CD7 (6A341) h(CD28-CD3ζ) CAR, pCDCAR1 Human 6A341 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP3302 Anti-CD7 (6A341) h(41BB-CD3ζ) CAR, pCDCAR1 Human 6A341 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP3303 Anti-CD7 (3H1751) h(CD28-CD3ζ) CAR, pCDCAR1 Human 3H1751 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP3304 Anti-CD7 (3H1751) h(41BB-CD3ζ) CAR, pCDCAR1 Human 3H1751 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP3305 Anti-CD7 (T1-H7) h(CD28-CD3ζ) CAR, pCDCAR1 Human T1-H7 Rat scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP3306 Anti-CD7 (T1-H7) h(41BB-CD3ζ) CAR, pCDCAR1 Human T1-H7 Rat scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP3375 Anti-CD7 (BA0230) h(CD28-CD3ζ) CAR, pCDCAR1 Human BA0230 Rabbit scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-ZP3376 Anti-CD7 (BA0230) h(41BB-CD3ζ) CAR, pCDCAR1 Human BA0230 Rabbit scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-0323-LX880 Anti-CD7 VHH(X3XH142) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 Vector Human X3XH142 VHH-CD28-OX40-CD3ζ Lentiviral vector T cell CAR-T   Add to Cart   Datasheet
XS-0323-LX881 Anti-CD7 VHH(X3XH143) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 Vector Human X3XH143 VHH-CD28-OX40-CD3ζ Lentiviral vector T cell CAR-T   Add to Cart   Datasheet
XS-0823-LX22 Anti-hCD7 (MAB) ICD(CD28-OX40-CD3ζ) CAR-MA, pAd5f35 Vector Human MAB Adenoviral vectors   Add to Cart   Datasheet
XS-0923-LX119 Anti-hCD7 (CD28-41BB-CD3ζ) CAR-duplex CTLA4 pCDCAR1 Vector Human X9X-88 scFv-CD28-41BB-CD3ζ-duplex CTLA4 Lentiviral vector T cell CAR-T   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.